nedosiran
Selected indexed studies
- Nedosiran. (, 2006) [PMID:40694643]
- Nedosiran: First Approval. (Drugs, 2023) [PMID:38060091]
- Nedosiran. (, 2012) [PMID:40112126]
_Worker-drafted node — pending editorial review._
Connections
nedosiran is a side effect of
Sources
- Nedosiran. (2006) pubmed
- Nedosiran: First Approval. (2023) pubmed
- Nedosiran. (2012) pubmed
- Nedosiran, a Candidate siRNA Drug for the Treatment of Primary Hyperoxaluria: Design, Development, and Clinical Studies. (2022) pubmed
- PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. (2023) pubmed
- Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3. (2024) pubmed
- Correction to: Nedosiran: First Approval. (2024) pubmed
- The growth of siRNA-based therapeutics: Updated clinical studies. (2021) pubmed
- Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4). (2023) pubmed
- PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1. (2025) pubmed